Neuromedica, Inc.

Protarga, Inc.

Other

Ischemix, LLC

Luitpold Pharmaceuticals, Inc.

The Mclean Hospital Corporation

Ceremedix, Inc.

Shashoua, Victor E.

Victor E Shashoua

Charles S Swindell

Matthews O Bradley

Nigel L Webb

Gary W Hesse

The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions.

Neuroprotective and neurorestorative methods and compositions

Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals, to upregulate AP-1 gene expression, and to treat pain. The peptide compounds may be used as components of pharmaceuticals and dietary supplements.

Compositions and methods for counteracting effects of reactive oxygen species and free radicals

Neuroprotective and neurorestorative method and compositions

The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

Fatty acid-pharmaceutical agent conjugates

The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

DHA-pharmaceutical agent conjugates of taxanes

The invention relates to neuroprotective peptides which bind calcium and which are useful in treating stroke and other neurodegenerative diseases, as well as compositions containing such peptides. The peptides preferably are conjugated to or administered with a compound which facilitates delivery across the blood-brain barrier.

Neuroprotective peptides and uses thereof

Dha-pharmaceutical agent conjugates to improve tissue selectivity

The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.

Method of treating a liver disorder with fatty acid-antiviral agent conjugates

The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

Dopamine analog amide

The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychological disorders such as schizophrenia.

Growing community of inventors

Brookline, MA, United States of America

Victor E Shashoua